Balaxi Pharmaceuticals Ltd.
•Add ratio to table
ABOUT
AI Sector View
AI GENERATEDOil Gas & Consumable Fuels
Sector economics are clouded by input volatility and uneven volume trends. WPI fuel inflation is very high at 20.05% (Jul/26), crude oil output is -5.3% YoY (2026-07), natural gas is -3.7% YoY (2026-07), and natural gas consumption is -3.0% YoY (2026-06), although refinery products grew 2.7% YoY (2026-07) and coal was 7.6% YoY (2026-07). Heavy FPI outflows of INR -15293 crore over 3 months to 2026-08-31 and negative oil-linked news flow reinforce the underweight.
PROS
- Strong cash generation - operating cash flow backs reported profits (CFO/PAT 2.78x)
- Working capital cycle has improved - days down from 454 to 67
- Company maintains a comfortable, low leverage position
CONS
- A large part of profit comes from other income (137.5% of PBT)
- Recent results are weak - TTM profit is down 52.9% versus prior year
- Company has a low return on equity of 3.5% over last 3 years
- Company has a low return on capital employed of 5.8%
- Operating cash flow has been negative in recent years
- Company's sales have been declining over the last five years
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| ADANIENT | 2959.80 | 53.82 | 400674.82 | 0.04 | -1461.54 | -249.67 | 32923.98 | 49.92 | 13.30 | 15.57 |
| CPPLUS | 3827.20 | 94.86 | 45275.94 | 0.04 | 142.20 | 332.51 | 1402.42 | 89.51 | 29.48 | 14.52 |
| PREMIERENE | 987.25 | 26.92 | 44816.36 | 0.10 | 471.92 | 53.32 | 2462.59 | 35.25 | 33.72 | 29.03 |
| AEGISLOG | 1268.20 | 35.57 | 44513.82 | 0.69 | 544.84 | 210.70 | 2356.86 | 37.07 | 19.76 | 30.28 |
| REDINGTON | 373.60 | 17.17 | 29207.09 | 1.61 | 453.49 | 94.65 | 34922.47 | 34.57 | 18.96 | 2.03 |
| HONASA | 475.35 | 62.27 | 15497.56 | 0.63 | 90.45 | 118.87 | 755.95 | 27.00 | 20.87 | 14.58 |
| LLOYDSENT | 71.04 | 96.58 | 10844.63 | 0.21 | 109.98 | -55.77 | 563.03 | 70.15 | 12.84 | 18.07 |
| SGMART | 808.80 | 81.99 | 10193.73 | 0.00 | 455.80 | 1310.71 | 13085.70 | 1044.08 | 10.43 | 4.49 |
| MMTC | 63.23 | 21.20 | 9484.50 | 0.00 | 104.24 | 135.52 | 0.68 | -50.00 | 33.46 | -1423.53 |
| ENTERO | 1855.60 | 64.40 | 8076.14 | 0.00 | 52.05 | 72.17 | 1940.50 | 38.23 | 10.93 | 5.00 |
| CELLO | 344.05 | 24.80 | 7759.64 | 0.44 | 73.40 | -8.99 | 526.72 | -0.43 | 17.15 | 18.80 |
| BALAXI | 23.34 | 53.16 | 128.85 | 0.00 | 1.30 | 347.24 | 80.68 | 14.05 | 3.48 | 5.78 |
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 25 | 17 | 13 | 16 | 19 | 21 | 11 | 10 | 17 | 19 | 25 | 20 | 16 | |
| 21 | 16 | 12 | 16 | 18 | 20 | 11 | 10 | 16 | 19 | 23 | 22 | 18 | |
| Operating Profit | 4 | 1 | 0 | 0 | 2 | 1 | 0 | -1 | 1 | 1 | 1 | -2 | -2 |
| OPM % | 15.06% | 5.50% | 2.20% | 1.26% | 7.93% | 6.99% | 0.90% | -6.74% | 3.23% | 3.99% | 5.61% | -9.54% | -13.04% |
| 0 | 1 | 1 | 0 | 1 | 1 | 3 | 0 | 0 | 4 | 2 | 3 | 1 | |
| Interest | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Profit before Tax | 4 | 2 | 1 | -0 | 2 | 2 | 2 | -1 | 0 | 4 | 2 | 0 | -1 |
| Tax % | 27.07% | 24.84% | 36.36% | -119.23% | 26.98% | 24.55% | 25.32% | -3.51% | 23.08% | 23.11% | 27.83% | 63.41% | -12.28% |
| Net Profit | 3 | 1 | 0 | -1 | 1 | 2 | 2 | -1 | 0 | 3 | 2 | 0 | -1 |
| 0.50 | 0.23 | 0.10 | -0.11 | 0.25 | 0.30 | 0.32 | -0.21 | 0.04 | 0.59 | 0.28 | 0.03 | -0.23 |
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 0 | 14 | 46 | 87 | 101 | 108 | 70 | 61 | 81 | 80 | |
| 0 | 1 | 12 | 37 | 68 | 84 | 91 | 65 | 58 | 80 | 82 | |
| Operating Profit | -0 | -1 | 2 | 9 | 19 | 17 | 17 | 5 | 3 | 1 | -2 |
| OPM % | — | — | 11.46% | 18.95% | 21.90% | 17.08% | 15.60% | 7.63% | 4.27% | 1.23% | -2.27% |
| 0 | 0 | 1 | 1 | 2 | 3 | 7 | 2 | 5 | 10 | 10 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 3 | 3 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 |
| Profit before Tax | -0 | -1 | 2 | 9 | 21 | 20 | 22 | 6 | 5 | 7 | 6 |
| Tax % | -0.00% | -0.00% | 19.41% | 29.29% | 26.53% | 25.54% | 27.74% | 34.62% | 31.89% | 26.82% | 34.79% |
| Net Profit | -0 | -1 | 2 | 6 | 15 | 15 | 16 | 4 | 4 | 5 | 4 |
| EPS | -0.57 | -2.53 | 6.47 | 8.65 | 15.13 | 14.67 | 16.02 | 3.35 | 0.65 | 0.93 | — |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 3.41% | 0.00% | 0.00% | 0.00% | 0.00% | — |
COMPOUNDED SALES GROWTH
- 10 Years:
- 110%
- 5 Years:
- -1%
- 3 Years:
- -9%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- —
- 5 Years:
- -19%
- 3 Years:
- -32%
STOCK PRICE CAGR
- 10 Years:
- 22%
- 5 Years:
- -26%
- 3 Years:
- -37%
- 1 Year:
- -49%
RETURN ON EQUITY
- 10 Years:
- 18%
- 5 Years:
- 13%
- 3 Years:
- 4%
- Last Year:
- 4%
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3 | 3 | 3 | 10 | 10 | 10 | 10 | 11 | 11 | 11 |
| -1 | -1 | 0 | 18 | 33 | 48 | 72 | 107 | 117 | 122 | |
| 0 | 0 | 0 | 0 | 4 | 2 | 12 | 16 | 32 | 35 | |
| Trade Payables | 0 | 0 | 2 | 7 | 17 | 16 | 17 | 12 | 9 | 18 |
| 0 | 0 | 1 | 3 | 6 | 6 | 18 | 8 | 5 | 6 | |
| Total Liabilities | 2 | 2 | 6 | 38 | 69 | 82 | 130 | 154 | 174 | 192 |
| 0 | 0 | 0 | 0 | 1 | 2 | 8 | 7 | 7 | 41 | |
| Capital Work in Progress | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 2 | 22 | 0 |
| 0 | 0 | 0 | 0 | 20 | 20 | 20 | 20 | 25 | 80 | |
| 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 77 | 90 | 64 | |
| Cash & Bank | 2 | 2 | 0 | 4 | 0 | 1 | 18 | 44 | 29 | 5 |
| 0 | 0 | 6 | 33 | 48 | 59 | 80 | 3 | 2 | 2 | |
| Total Assets | 2 | 2 | 6 | 38 | 69 | 82 | 130 | 154 | 174 | 192 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0 | -1 | -1 | -14 | 16 | 15 | -2 | -2 | -8 | 44 | |
| Cash from Investing | 3 | -0 | -0 | -0 | -20 | -7 | -2 | 0 | -25 | -68 |
| Cash from Financing | -0 | 0 | 0 | 18 | 3 | -2 | 26 | 28 | 17 | 1 |
| 2 | -1 | -2 | 3 | -3 | 0 | 17 | 26 | -15 | -23 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
2026-09-07 - BALAXI PHARMACEUTICALS LIMITED has informed the Exchange regarding '''RTA Report for Re-lodgement of Transfer Requests of Physical Shares for the period ended August 2026 .'.
2026-08-31 - Balaxi Pharmaceuticals Limited has informed the Exchange about the receipt of WHO-GMP Certification for Company's Pharmaceutical Formulation Manufacturing Facility.
2026-08-24 - BALAXI PHARMACEUTICALS LIMITED has informed the Exchange regarding Change in Director(s) of the company.
2026-08-24 - BALAXI PHARMACEUTICALS LIMITED has submitted the Exchange a copy Srutinizers Report of Annual General Meeting held on 24th August, 2026. Further, the company has informed the Exchange regarding Voting Results.
2026-08-24 - BALAXI PHARMACEUTICALS LIMITED has informed the Exchange regarding Proceedings of the 83rd Annual General Meeting held on 24th August, 2026
2026-08-14 - BALAXI PHARMACEUTICALS LIMITED has informed the Exchange about Copy of Newspaper Publication.
2026-08-11 - BALAXI PHARMACEUTICALS LIMITED has informed the Exchange about Copy of Newspaper Publication.
2026-08-10 - BALAXI PHARMACEUTICALS LIMITED has informed the Exchange regarding Corrigendum to Notice of the 83rd Annual General Meeting.
2026-08-07 - BALAXI PHARMACEUTICALS LIMITED has informed the Exchange regarding '''RTA Report for Re-lodgement of Transfer Requests of Physical Shares for the period ended July 2026".
News
Recent coverage and analyst commentary for BALAXI
Loading news…
AI Stock Analyst
Balaxi Pharmaceuticals Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account